Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas

Abstract

Microvessel density (MVD) is considered to be a prognostic marker in many tumours. Nevertheless, conflicting results were achieved regarding its prognostic role in meningiomas when it was quantified through pan-endothelial markers such as CD34, CD31 or Factor VIII. In the present study, MVD was assessed in meningiomas through the specific marker for neo-angiogenesis CD105. Fifty-four formalin fixed, paraffin embedded, surgical cases of meningiomas (WHO 28 grade I and 26 grade II) as well as ten normal leptomeningeal samples were submitted to immunohistochemical analysis for CD105. CD34 immuno-expression was also evaluated on consecutive parallel sections. For each case, MVD was estimated in terms of number of vessels/mm(2). CD105 was not evidenced in normal samples, whereas it was demonstrated in the vessels within 14/28 WHO grade I cases and within 24/26 WHO grade II meningiomas. On the contrary, CD34 antibody stained blood vessels in both normal and neoplastic samples; moreover, in each case, it stained more microvessels than CD105 antibody (25.33 +/- 21.16 vs. 50.72 +/- 26.75). Higher CD105 counts were significantly correlated with higher histological grade and Ki-67 LI > 4%. No statistical significant correlations were encountered between MVD measured by either CD105 and CD34 and sex, age, site of tumour or extent of surgical resection. CD105-MVD, but not CD34-MVD, showed an inverse significant correlation with overall survival and recurrence-free survival. In conclusion, our study suggests the higher specificity of CD105 in comparison to pan-endothelial markers in the evaluation of meningioma neo-angiogenesis, and its higher prognostic significance. CD105 might serve as a target for therapeutic approaches blocking blood supply in meningiomas.

Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study

“…Mean microvessel density has been correlated with risk of metastasis, prediction of efficacy of anticancer therapy, and prognosis in a variety of tumour types (Des Guetz et al, 2006;Gadducci et al, 2006;Zhao et al, 2006;Barresi et al, 2007;Calvin et al, 2007;Gulubova and Vlaykova, 2007;Kavantzas et al, 2007;Trivella et al, 2007). The PCI results agree with Eberhard's data (Eberhard et al, 2000).…”

BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma

“…[36][37][38] CD105 expression on endothelial cells is related to tumor progression in squamous cell carcinoma, 16 glioblastomas, 15 and meningiomas. 14 It correlates with survival in primary central nervous system lymphomas. 17 In our study using immunostainings and laser-microdissection combined with molecular analyses, we demonstrate that in angioimmunoblastic T-cell lymphoma, only CD34 þ CD105 þ neoangiogenic endothelial cells expressed BCL2.…”

“…13 In meningiomas, glioblastomas, and squamous cell carcinoma, CD105 expression on endothelial cells is related to neoangiogenesis and to tumor progression. [14][15][16] CD105 is also expressed by endothelial cells in the primary central nervous system lymphomas and correlates with survival. 17 Here, we studied BCL2 and VEGFA expression in neoangiogenic endothelial cells and lymphoma cells in angioimmunoblastic T-cell lymphoma.…”

The Oncofetal Protein IMP3: A Novel Molecular Marker to Predict Aggressive Meningioma

“…[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] Among them, Ki-67 (MIB-1), a tumor proliferation antigen, appears to be the best and is widely accepted as a biomarker for meningioma prognosis. As a general rule, the Ki-67 proliferation index correlates well with WHO tumor grade for meningioma.…”